Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceuticals has raised $175.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2025.
Amylyx Pharmaceuticals's investors include Alpha Wave Global, Perceptive Advisors, Bain Capital Life Sciences, Rock Springs Capital, Viking Global Investors.
Amylyx Pharmaceuticals is headquartered in Cambridge, United States.
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amylyx Pharmaceuticals — Funding & Investors." VCBacked, September 10, 2025, https://www.vcbacked.co/company/amylyx-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2025). Amylyx Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/amylyx-pharmaceuticals
{{cite web |title=Amylyx Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/amylyx-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated